ScreenerHero

ACAD Acadia Pharmaceuticals Inc.

NAS · US · Healthcare · Biotechnology · acadia.com
19.65USD-0.46%Mkt Cap: 3.36B $P/E: 8.81

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a se…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.36B USD
Enterprise Value2.52B USD
Revenue (TTM)1.14B USD
Gross Profit982.51M USD
Net Income (TTM)391.00M USD
Revenue/Share6.69 USD
Last Price19.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees796
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)8.81
P/E (Forward)22.22
PEG50.86
EV/EBITDA25.60
EV/Revenue2.21
P/S2.97
P/B2.60
EPS (TTM)2.19
EPS (Forward)0.89
52W Range
19.452% of range30.96
52W High30.96 USD
52W Low19.45 USD
Profitability
Gross Margin91.69%
Oper. Margin12.29%
EBITDA Margin8.64%
Profit Margin36.49%
ROE31.86%
ROA25.00%
Growth
Revenue Growth16.40%
Earnings Growth13.30%
Cash Flow & Leverage
Operating CF109.84M USD
CapEx (TTM)4.69M USD
FCF Margin6.03%
FCF Yield2.04%
Net Debt-882.62M USD
Net Debt/EBITDA-8.97
Balance Sheet
Debt/Equity0.04
Current Ratio3.39
Quick Ratio3.11
Book Value/Sh7.59 USD
Cash/Share5.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.16 USD
Upside (mean)+63.7%
Target Range17.00 USD – 49.00 USD
17.00+63.7% to mean49.00
# Analysts19
Ownership
Shares Out.171.24M
Float128.35M
Insiders0.33%
Institutions99.64%
Short Interest
Short Ratio6.9d
Short % Float8.87%
Short % Out.5.61%
Shares Short9.67M
Short (prev mo.)9.48M
Technical
SMA 5026.74 (-26.5%)
SMA 20024.33 (-19.2%)
Beta0.89
S&P 52W Chg16.45%
Avg Vol (30d)2.10M
Avg Vol (10d)3.07M
Technical Indicators
RSI (14)18.6
MACD-2.1151
MACD Signal-1.6898
MACD Hist.-0.4253
BB Upper30.77 USD
BB Middle23.69 USD
BB Lower16.60 USD
BB Width59.83%
ATR (14)0.8975 USD
Vol Ratio (20d)0.74x